Evidence map›Paper›PMID 26747451›Full record

ArticleBMC biotechnology2016

HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species.

Gaily Kivi, Kaupo Teesalu, Jüri Parik, Elen Kontkar, Mart Ustav, Liis Noodla, Mart Ustav, Andres Männik

Abstract read
In one paragraph

Article in BMC biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Seven classes of antiviral agents.Cellular and molecular life sciences : CMLS · 2022
    Review
  5. Article
  6. Article
  7. Article
  8. Expanding the Malaria Antibody Toolkit: Development and Characterisation ofFrontiers in cellular and infection microbiology · 2022
    Article
  9. Article
  10. Article
  11. Development of monoclonal antibodies against axenic amastigotes ofIranian journal of basic medical sciences · 2018
    Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gaily KiviIcosagen Cell Factory OÜ, Eerika tee 1, Õssu village, Ülenurme parish, Tartumaa, 61713, Estonia. gaily.kivi@icosagen.ee.
Kaupo TeesaluIcosagen Cell Factory OÜ, Eerika tee 1, Õssu village, Ülenurme parish, Tartumaa, 61713, Estonia. kaupo.teesalu@icosagen.ee.
Jüri ParikEstonian Biocentre, Evolutionary Biology Group, Tartu, 51010, Estonia. jyri.parik@gmail.com.
Elen KontkarIcosagen Cell Factory OÜ, Eerika tee 1, Õssu village, Ülenurme parish, Tartumaa, 61713, Estonia. elen.kontkar@gmail.com.
Mart UstavUniversity of Tartu, Institute of Technology, Nooruse1, Tartu, 50411, Estonia. mart.ustav.jr@ut.ee.
Liis NoodlaUniversity of Tartu, Institute of Technology, Nooruse1, Tartu, 50411, Estonia. Liis.Noodla@entsik.ee.
Mart UstavIcosagen Cell Factory OÜ, Eerika tee 1, Õssu village, Ülenurme parish, Tartumaa, 61713, Estonia. mart.ustav@icosagen.ee.
Andres MännikIcosagen Cell Factory OÜ, Eerika tee 1, Õssu village, Ülenurme parish, Tartumaa, 61713, Estonia. andres.mannik@icosagen.ee.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe production of recombinant monoclonal antibodies in mammalian cell culture is of high priority in research and medical fields. A critical step in this process is the isolation of the antigen-binding domain sequences of antibodies possessing the desired properties. Many different techniques have been described to achieve this goal, but all have shortcomings; most techniques have problems with robustness, are time-consuming and costly, or have complications in the transfer from isolation to production phase. Here, we report a novel HybriFree technology for the development of monoclonal antibodies from different species that is robust, rapid, inexpensive and flexible and can be used for the subsequent production of antibodies in mammalian cell factories.

resultsHybriFree technology is illustrated herein via detailed examples of isolating mouse, rabbit and chicken monoclonal antibody sequences from immunized animals. Starting from crude spleen samples, antigen capturing of specific B-cells is performed initially. cDNA of antibody variable domains is amplified from the captured cells and used a source material for simple and rapid restriction/ligation free cloning of expression vector library in order to produce scFv-Fc or intact IgG antibodies. The vectors can be directly used for screening purposes as well as for the subsequent production of the developed monoclonal antibodies in mammalian cell culture. The antibodies isolated by the method have been shown to be functional in different immunoassays, including ELISA, immunofluorescence and Western blot. In addition, we demonstrate that by using a modified method including a negative selection step, we can isolate specific antibodies targeting the desired epitope and eliminate antibodies directed to undesired off-targets.

conclusionsHybriFree can be used for the reliable development of monoclonal antibodies and their subsequent production in mammalian cells. This simple protocol requires neither the culturing of B-cells nor single-cell manipulations, and only standard molecular biology laboratory equipment is needed. In principle, the method is applicable to any species for which antibody cDNA sequence information is available.

Indexed as

Amino Acid SequenceAnimalsAntibodies, MonoclonalB-LymphocytesChickensCytological TechniquesDNA, ComplementaryFemaleImmunoassayMiceMice, Inbred BALB CMolecular Sequence DataPeptide LibraryRabbitsRecombinant ProteinsAntibodies, MonoclonalDNA, ComplementaryPeptide LibraryRecombinant Proteins

Identifiers

PMID26747451
PMCPMC4706699

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.